Clinical Trials Directory

Trials / Unknown

UnknownNCT05009563

COvid iMaging With POSitron Emission Tomography

Evaluation of COVID-19 by Whole-body FDG-PET/CT

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Semmelweis University Heart and Vascular Center · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

We aim to study if metabolic intensity and extent according to pathologic pulmonary 18F-2-fluoro-2-deoxy-D-glucose (FDG)-uptake may correlate with the course of COVID-19 pneumonia and potentially yield prognostic value. Moreover, we aim to assess permanent changes after Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, such as pulmonary fibrosis and neuropsychiatric symptoms (anosmia, depression, fatigue) where evaluation with FDG-positron emission tomography (PET/CT) might have an impact on further patient care.

Detailed description

Several case studies confirmed increased FDG-uptake on PET scans corresponding to typical pulmonary lesions on chest CT scans in patients with COVID-19 pneumonia. Furthermore, increased FDG-uptake most likely caused by inflammatory changes in SARS-CoV-2 infection were described in other organs, such as mediastinal lymph nodes, bone marrow, and the spleen. As COVID-19 frequently presents with anosmia and on rare occasions, symptoms of encephalitis, metabolic changes in the central nervous system (CNS) were also investigated by FDG-PET/CT, showing hypometabolism in the olfactory gyrus and the limbic system, while hypermetabolism was observed in the basal ganglia and the cerebellar vermis. Late changes in pulmonary CT-morphology, most commonly interstitial thickening and crazy paving are observed, suggesting permanent lung damage after SARS-CoV-2 infection in certain cases. Evaluation of metabolic activity of acute and late inflammatory changes could potentially provide clinical benefit as dedicated medication could be started to prevent further organ damage due to prolonged inflammation. We aim to evaluate metabolic alterations in the lung parenchyma and potential extrapulmonary locations related to to COVID-19 with FDG-PET/CT.

Conditions

Interventions

TypeNameDescription
RADIATIONFDG-PET/CTwhole-body F-18-fluoro-deoxy-glucose positron emission tomography/computed tomography

Timeline

Start date
2021-01-04
Primary completion
2022-01-04
Completion
2022-01-04
First posted
2021-08-17
Last updated
2021-08-17

Locations

1 site across 1 country: Hungary

Source: ClinicalTrials.gov record NCT05009563. Inclusion in this directory is not an endorsement.